Description: Antidiabetic Agent, Dipeptidyl Peptidase 4 (DPP-4) Inhibitor; Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
CSA NA – FDA Approved – REMS (N) – Can Ship
How Does It Work
Glyxambi is an antidiabetic drug that combines empagliflozin and Linagliptin. Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, reduces the reabsorption of filtered glucose resulting in increased urinary excretion of glucose, thereby lowering blood glucose levels. Linagliptin inhibits the dipeptidyl peptidase 4 (DPP-4) enzyme resulting in prolonged active incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) regulating glucose level by increasing insulin synthesis and secretion while decreasing glucagon secretion.
Indications For Use
Diabetes mellitus, type 2
Before starting Empagliflozin+Linagliptin, Glyxambi makes sure your physician is aware of any allergies or medications you currently take, and activities you perform. Empagliflozin+Linagliptin, Glyxambi has been reported to cause arthralgia, bone fractures, genital infections, ketoacidosis, hypotension, necrotizing fasciitis, pancreatitis, renal effects, and urinary tract infections.
Usual (Oral): Take one tablet (empagliflozin 10mg/linagliptin 5mg) once daily; may increase to (empagliflozin 25mg/linagliptin 5mg) once daily.
Pharmacist Tips On Using
How to Take Empagliflozin+Linagliptin, Glyxambi: Take one tablet once daily in the morning with or without food.
Urinary tract infection, hypoglycemia, upper respiratory tract infection, nasopharyngitis
Note this is not a complete list of side effects, only the most common.
Frequently Asked Questions
What do I do if the side effects are not tolerable?
If the side effects are causing a lot of distress speak to our physician as soon as possible to discuss options.